LONDON, March 16, 2026, 17:25 GMT
- GSK closed out Monday at 2,026 pence, slipping 0.25%.
- GSK repurchased 445,000 shares on March 13, paying an average of 2,041.70 pence each, according to a company filing.
- Weaker vaccine momentum and a tempered 2026 outlook have investors sizing up shareholder returns.
GSK shares edged down Monday, despite the company announcing fresh buyback activity. The British drugmaker’s stock finished the day at 2,026 pence on the London exchange, off 0.25%. That’s a notch below the 2,041.70 pence average GSK shelled out to repurchase its own shares on March 13, according to market data and a company filing. Investors appear to be holding out for a more substantial catalyst.
This step comes as GSK works to steady investor sentiment, with growth slowing compared to last year and expectations rising for its latest drugs to deliver. While buybacks tend to boost per-share earnings—since profits are divided among fewer shares—they leave unresolved the broader concern: can new launches and deals really make up for strains in its legacy segments?
GSK disclosed in a Monday filing that it bought back 445,000 ordinary shares on March 13, paying between 2,027 and 2,060 pence per share. Following that transaction, the company reported holding 249.8 million shares in treasury—shares sitting on its own balance sheet—representing 6.14% of the voting rights.
These trades are part of the fourth leg of GSK’s 2 billion-pound buyback program. Back on Feb. 17, the company announced this particular tranche could reach 450 million pounds in purchases, running through April 24, aimed at pushing excess cash back to shareholders and boosting earnings per share.
Share count only scratches the surface of the thesis here. On March 13, GSK’s Arexvy RSV vaccine picked up expanded FDA approval, now including at-risk adults ages 18 to 49. That unlocks an additional market—though GSK will soon be up against Moderna’s mRESVIA and Pfizer’s Abrysvo, once the CDC issues its recommendation for these younger adults.
GSK shares were already on a tear heading into Monday. Back on Feb. 4, the stock surged 5.6%—touching highs not seen in almost 25 years—after new CEO Luke Miels reiterated the company’s more than 40 billion pound sales target for 2031. Sheena Berry at Quilter Cheviot described the guidance as a “steady and credible start” for Miels. Reuters
Risks haven’t disappeared. Back in February, GSK flagged that 2026 revenue growth would land between 3% and 5%—a step down from what’s expected in 2025. The company also projected vaccine and general medicines sales would likely hold steady or slip a bit. Barclays analysts, according to Reuters, called those numbers a touch under consensus, pointing mostly to foreign-exchange headwinds.
At this point, GSK shares remain hemmed in—capital returns offer a floor, but skepticism persists on what drives the next move higher. The stock ended Monday far under its 52-week high of 2,282 pence, even with the FTSE 100 up 0.55%. Investors seem less interested in the ongoing buybacks and more in seeing a concrete commercial or pipeline spark.
